<DOC>
	<DOCNO>NCT01157351</DOCNO>
	<brief_summary>The study ass use paliperidone palmitate compare oral antipsychotic treatment delay time protocol-defined treatment failure 15 month , patient diagnose schizophrenia incarcerate .</brief_summary>
	<brief_title>15 Month Study Adults Who Have Been Diagnosed With Schizophrenia Incarcerated</brief_title>
	<detailed_description>The primary objective study compare efficacy paliperidone palmitate oral antipsychotic treatment delay time protocol-defined treatment failure 15 month , patient diagnose schizophrenia incarcerate . Protocol-defined treatment failure define arrest , psychiatric hospitalization , increase psychiatric service prevent imminent hospitalization , discontinuation antipsychotic treatment due inadequate efficacy , treatment supplementation another antipsychotic due inadequate efficacy , discontinuation antipsychotic treatment due safety tolerability complete suicide . Protocol amend March 15 , 2011 reflect change inclusion/exclusion criterion well study objective . Patients receive either paliperidone palmitate 78 , 117 , 156 , 234 mg monthly injection fifteen month OR oral aripiprazole , haloperidol , olanzapine , paliperidone , perphenazine , quetiapine , risperidone dos select study doctor .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Perphenazine</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Must able understand sign inform consent form approve Institutional Review Board ( IRB ) Must successfully answer question Informed Consent quiz indicate understand purpose procedure require study willing participate study Have current diagnosis schizophrenia Taking 1 oral antipsychotic day randomization Have place custody least twice one lead incarceration within 24 month previous study start , last release occur within 90 day first day screen opinion investigator , may benefit change prior antipsychotic treatment Have available designate individual ( eg , family member , case manager , significant , probation/parole officer ) knowledge patient generally aware patient 's daily activity , agree let study site personnel know change patient circumstance patient able provide information , ie , arrest , protocoldefined hospitalization , emergency room visit , become homeless , etc . Have either address phone number reach , accessible designate individual Must agree receive regular injection 15 month randomly assign paliperidone palmitate treatment group , continue oral study medication treatment 15 month randomly assign oral antipsychotic treatment group Women must postmenopausal ( least 2 year ) , surgically sterile ( hysterectomy bilateral oophorectomy , tubal ligation , otherwise incapable pregnancy ) , abstinent , sexually active , practice highly effective method birth control Allergies , hypersensitivity ( anaphylaxistype reaction ) , intolerance risperidone paliperidone Actively abuse intravenous drug within past 3 month opiate dependence disorder Have positive urine drug screen test barbiturate , cocaine , amphetamine , opiates screen Women pregnant breastfeeding , plan become pregnant Have receive injectable antipsychotic treatment within 2 injection cycle prior screen Received treatment clozapine within 3 month screen Are high risk violence next 15 month , opinion investigator history sex offenses include felony sex offense , child molestation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Risperidone</keyword>
	<keyword>Risperdal</keyword>
	<keyword>Paliperidone palmitate</keyword>
	<keyword>Aripiprazole</keyword>
	<keyword>Haloperidol</keyword>
	<keyword>Olanzapine</keyword>
	<keyword>Paliperidone</keyword>
	<keyword>Perphenazine</keyword>
	<keyword>Quetiapine</keyword>
</DOC>